Sign In
Buy ANNX
$5.39
+0.130 (+2.47%)
At Close: Jun 03, 2026
What Makes Annexon (ANNX) a New Buy Stock
01:00pm, Monday, 01'st Apr 2024
Annexon (ANNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade
10:56am, Monday, 01'st Apr 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 101.1% in Annexon (ANNX). While the effectiveness of this highly sought-after metric is questionable, the posit
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
04:05pm, Tuesday, 26'th Mar 2024
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024,
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 18'th Mar 2024
BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living wit
Why Annexon (ANNX) Might Surprise This Earnings Season
09:40am, Thursday, 14'th Mar 2024
Annexon (ANNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
08:00am, Tuesday, 27'th Feb 2024
BRISBANE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach
08:00am, Wednesday, 21'st Feb 2024
Virtual event on Friday, March 1, 2024 at 10:00 AM ET Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 20'th Feb 2024
BRISBANE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
10:40am, Thursday, 18'th Jan 2024
Here is how Annexon, Inc. (ANNX) and Novartis (NVS) have performed compared to their sector so far this year.
Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How
12:11pm, Wednesday, 17'th Jan 2024
Annexon (ANNX) has rallied 156% in the past three months on plans to begin a registrational program for ANX007 in GA after reaching FDA alignment on the study's primary endpoint.
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
06:30am, Wednesday, 27'th Dec 2023
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with
Annexon: ANX007 Advances Forward With Stellar Endpoint
12:00pm, Saturday, 23'rd Dec 2023
Alignment with FDA reached to have phase 3 ARROW study use Best Corrected Visual Acuity ≥ 15-Letter Loss as the primary endpoint; Significance of this could mean competitive advantage. A sham-contro
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
06:30am, Tuesday, 19'th Sep 2023
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with cla
Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX)
11:18am, Friday, 08'th Sep 2023
Annexon, Inc. (ANNX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
06:30am, Monday, 24'th Jul 2023
Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET
